- Home
- ADVM
as 05-09-2025 4:00pm EST
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 59.5M | IPO Year: | 2014 |
| Target Price: | $26.60 | AVG Volume (30 days): | 521.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.62 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.64 - $10.84 | Next Earning Date: | 05-20-2025 |
| Revenue: | $1,000,000 | Revenue Growth: | -72.22% |
| Revenue Growth (this year): | -83.85% | Revenue Growth (next year): | 42.58% |
Stock Insider Trading Activity of Adverum Biotechnologies Inc. (ADVM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Leonard Braden Michael | ADVM | 10% Owner | Apr 22 '25 | Buy | $2.99 | 350,000 | $1,048,950.00 | 191,800 | |
| Leonard Braden Michael | ADVM | 10% Owner | Mar 31 '25 | Buy | $4.21 | 34,775 | $147,075.63 | 191,800 | |
| Leonard Braden Michael | ADVM | 10% Owner | Mar 26 '25 | Buy | $5.11 | 111,000 | $566,791.62 | 191,800 | |
| Leonard Braden Michael | ADVM | 10% Owner | Mar 18 '25 | Buy | $4.97 | 117,941 | $587,574.62 | 191,800 | |
| Leonard Braden Michael | ADVM | 10% Owner | Feb 26 '25 | Buy | $4.35 | 336,756 | $1,439,087.09 | 191,800 |
Latest Adverum Biotechnologies Inc. News
ADVM Breaking Stock News: Dive into ADVM Ticker-Specific Updates for Smart Investing
Simply Wall St.
6 days ago
3 Penny Stocks Under $300M Market Cap To Consider
GlobeNewswire
10 days ago
Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Argus Research
13 days ago
Daily – Vickers Top Buyers & Sellers for 04/29/2025
MT Newswires
18 days ago
Adverum Biotechnologies Insider Bought Shares Worth $1,048,950, According to a Recent SEC Filing
MT Newswires
21 days ago
Truist Removes $40 Price Target on Adverum Biotechnologies, Cites Share Volatility, Keeps Buy Rating
MT Newswires
a month ago
RBC Cuts Price Target on Adverum Biotechnologies to $5 From $10, Keeps Sector Perform, Speculative Risk
Associated Press Finance
a month ago
Adverum Biotechnologies: Q4 Earnings Snapshot
GlobeNewswire
a month ago
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Pipeline Highlights and Updates to Anticipated Milestones
Compare ADVM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ADVM Adverum Biotechnologies Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.